The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder
Alexander S. Baras(Johns Hopkins University), Trinity J. Bivalacqua(University of Pennsylvania), Alan K. Meeker(Johns Hopkins University), Charles G. Drake(Columbia University Irving Medical Center), Janis M. Taube(Bloomberg (United States)), George J. Netto(University of Pennsylvania), Jen‐Jane Liu(Johns Hopkins University), Nilay Gandhi(Johns Hopkins University), Mark Schoenberg(Montefiore Medical Center), Noah M. Hahn(Johns Hopkins University), Max Kates(Duke Medical Center), Mohammad Obaidul Hoque(Johns Hopkins University)
Cited by 174
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k